ODM derived from

  1. 11-12-13 11-12-13 - Martin Dugas
  2. 14-04-14 14-04-14 - Julian Varghese
  3. 02-09-21 02-09-21 -
  4. 20-09-21 20-09-21 -
Geüploaded op:

20 september 2021

Voor een aanvraag inloggen.
Licentie :
Creative Commons BY 4.0
Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility NCT00332709 Osteoporosis. Postmenopausal


  1. StudyEvent: Eligibility
    1. Eligibility
Alter 18 Jahre und älter
Compliant postmenopausal women with primary operable breast cancer after 4 to 6 years of therapy with tamoxifen (end of tamoxifen therapy within last 6 months)
ECOG Status
Patients without severe osteoporosis at study entry
No evidence of relapse at the time of randomization
Adequate function of bone marrow, kidney, and liver
Estrogen- and progesterone-receptor status negative or unknown
Completion of adjuvant tamoxifen therapy more than 6 months prior to study start
Inflammatory Breast Carcinoma, Mastitis carcinomatosa
Current/active dental problems including infection of the teeth or jawbone, dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw, of exposed bone in the mouth, or of slow healing after dental procedures
Recent (within 6 weeks) or planned dental or jaw surgery
History of diseases with influence on bone metabolism such as Paget's disease and primary overactive parathyroid
Prior or concomitant therapies: chemotherapy within the last 12 months, intravenous or oral bisphosphonates, systemic corticosteroids, anabolic steroids or growth hormones, Tibolone, parathyroid hormone, systemic sodium fluoride or any drugs known to affect the skeleton (such as calcitonin, mithramycin, or gallium nitrate)
Patients with previous or concomitant cancers (not breast cancer) within the past 5 years EXCEPT adequately treated basal or squamous cell skin cancers or in situ cancer of the cervix. Patients with previous other cancer(s) must have been disease-free for at least 5 years.
Patients currently receiving oral bisphosphonates must discontinue these at least 3 weeks prior to study start.

Similar models

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial